JLK 6
Biological Activity
Inhibitor of γ-secretase that selectively inhibits βAPP cleavage without affecting other γ-secretase-mediated pathways. Prevents recovery of Aβ40 and Aβ42 from HEK293 cell overexpressing wild-type or Swedish-mutated βAPP (IC50 ~ 30 μM) but displays no effect on Notch cleavage and Notch-mediated intracellular signaling. Displays no activity on BACE1, BACE2, α-secretase, the proteosome or GSK3β.
Technical Data
| M. Wt | 225.63 |
| Formula | C10H8ClNO3 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 62252-26-0 |
| PubChem ID | 3803 |
| InChI Key | AMDGKLWVCUXONP-UHFFFAOYSA-N |
| Smiles | COC1=C(Cl)C2=CC=C(N)C=C2C(=O)O1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 22.56 | 100 | |
| ethanol | 5.64 | 25 |
Preparing Stock Solutions
The following data is based on the product molecular weight 225.63. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.43 mL | 22.16 mL | 44.32 mL |
| 5 mM | 0.89 mL | 4.43 mL | 8.86 mL |
| 10 mM | 0.44 mL | 2.22 mL | 4.43 mL |
| 50 mM | 0.09 mL | 0.44 mL | 0.89 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the biological activity of the product.
Petit et al (2001) New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage. Nat.Cell.Biol. 3 507 PMID: 11331880
Petit et al (2003) JLK isocoumarin inhibitors: selective γ-secretase inhibitors that do not interfere with Notch pathway in vitro or in vivo. J.Neurosci.Res. 74 370 PMID: 14598313
Hellstrom et al (2007) DII4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445 776 PMID: 17259973
If you know of a relevant reference for JLK 6, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: JLK 6, JLK 6 supplier, inhibitors, inhibits, γ-secretase, gamma-secretase, mediated, βAPP, betaAPP, processing, Proteinases, Proteases, β-Amyloid, beta-Amyloid, b-amyloid, Precursor, Protein, APP, beta, Peptides, JLK6, amyloidbeta, amyloidb, amyloidβ, Gamma-Secretase, Amyloid, Beta, 2677, Tocris Bioscience
Citations for JLK 6
Citations are publications that use Tocris products.
Currently there are no citations for JLK 6. Do you know of a great paper that uses JLK 6 from Tocris? Please let us know.
Reviews for JLK 6
There are currently no reviews for this product. Be the first to review JLK 6 and earn rewards!
Have you used JLK 6?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and Europe
Submit a ReviewLiterature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
